163 related articles for article (PubMed ID: 33239969)
1. A Trend Toward Aggressive Prostate Cancer.
Shah N; Ioffe V
Rev Urol; 2020; 22(3):102-109. PubMed ID: 33239969
[TBL] [Abstract][Full Text] [Related]
2. Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men.
Shah N; Ioffe V; Cherone S
Rev Urol; 2019; 21(1):1-7. PubMed ID: 31239823
[TBL] [Abstract][Full Text] [Related]
3. Increasing aggressive prostate cancer.
Shah N; Ioffe V; Chang JC
Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
[TBL] [Abstract][Full Text] [Related]
4. Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.
Shah N; Ioffe V; Huebner T; Hristova I
Rev Urol; 2018; 20(2):77-83. PubMed ID: 30288144
[TBL] [Abstract][Full Text] [Related]
5. Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.
Shah N; Huebner T; Ioffe V; Hum R
Rev Urol; 2017; 19(1):25-31. PubMed ID: 28522927
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
7. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
8. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
[TBL] [Abstract][Full Text] [Related]
11. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
[TBL] [Abstract][Full Text] [Related]
12. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
13. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
Roscigno M; Scattoni V; Freschi M; Abdollah F; Maccagnano C; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Deiana G; Belussi D; Chinaglia D; Montorsi F; Da Pozzo LF
BJU Int; 2012 May; 109(9):1329-34. PubMed ID: 21895935
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of high-grade prostatic intraepithelial neoplasia: the impact of the number of biopsy cores at initial sampling on cancer detection after a saturation re-biopsy.
Roscigno M; Scattoni V; Freschi M; Raber M; Angiolilli D; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Feroldi L; Deiana G; Chinaglia D; Montorsi F; Da Pozzo LF
Arch Ital Urol Androl; 2010 Dec; 82(4):242-7. PubMed ID: 21341572
[TBL] [Abstract][Full Text] [Related]
17. Need for and relevance of prostate cancer screening in Nigeria.
Akinremi T; Adeniyi A; Olutunde A; Oduniyi A; Ogo C
Ecancermedicalscience; 2014; 8():457. PubMed ID: 25228913
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
